[go: up one dir, main page]

DE10075011I2 - Rezeptoren für Tumornekrosisfaktor-alpha und-beta. - Google Patents

Rezeptoren für Tumornekrosisfaktor-alpha und-beta.

Info

Publication number
DE10075011I2
DE10075011I2 DE2000175011 DE10075011C DE10075011I2 DE 10075011 I2 DE10075011 I2 DE 10075011I2 DE 2000175011 DE2000175011 DE 2000175011 DE 10075011 C DE10075011 C DE 10075011C DE 10075011 I2 DE10075011 I2 DE 10075011I2
Authority
DE
Germany
Prior art keywords
necrosis factor
tumor necrosis
receptors
beta
factor alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE2000175011
Other languages
English (en)
Other versions
DE10075011I1 (de
Inventor
Craig Smith
Raymond Goodwin
Patricia Beckmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10075011(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DE10075011I1 publication Critical patent/DE10075011I1/de
Publication of DE10075011I2 publication Critical patent/DE10075011I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
DE2000175011 1989-09-11 1990-09-10 Rezeptoren für Tumornekrosisfaktor-alpha und-beta. Active DE10075011I2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40537089A 1989-09-11 1989-09-11
US42141789A 1989-10-13 1989-10-13
US07/523,635 US5395760A (en) 1989-09-05 1990-05-10 DNA encoding tumor necrosis factor-α and -β receptors

Publications (2)

Publication Number Publication Date
DE10075011I1 DE10075011I1 (de) 2003-06-12
DE10075011I2 true DE10075011I2 (de) 2004-08-12

Family

ID=27410621

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69024291T Expired - Lifetime DE69024291T2 (de) 1989-09-11 1990-09-10 Rezeptoren für Tumornekrosisfaktor-alpha und -beta
DE2000175011 Active DE10075011I2 (de) 1989-09-11 1990-09-10 Rezeptoren für Tumornekrosisfaktor-alpha und-beta.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69024291T Expired - Lifetime DE69024291T2 (de) 1989-09-11 1990-09-10 Rezeptoren für Tumornekrosisfaktor-alpha und -beta

Country Status (9)

Country Link
US (2) US5395760A (de)
EP (1) EP0418014B1 (de)
AT (1) ATE131871T1 (de)
DE (2) DE69024291T2 (de)
DK (1) DK0418014T3 (de)
ES (1) ES2080809T4 (de)
GR (1) GR3019333T3 (de)
LU (1) LU90591I2 (de)
NL (1) NL300008I2 (de)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479632B1 (en) 1988-09-12 2002-11-12 Yeda Research And Development Co. Ltd. Tumor necrosis factor inhibitory protein and its purification
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
EP0393438B1 (de) * 1989-04-21 2005-02-16 Amgen Inc. TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US6232446B1 (en) 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
CA2017025C (en) * 1989-05-18 2008-07-22 David Wallach Tumor necrosis factor binding protein ii, its purification and antibodies thereto
US6262239B1 (en) 1989-05-18 2001-07-17 Yeda Research And Development Co., Ltd. TNF receptor-specific antibodies
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US6451983B2 (en) 1989-08-07 2002-09-17 Peptech Limited Tumor necrosis factor antibodies
DE69027121T3 (de) 1989-08-07 2001-08-30 Peptech Ltd., Dee Why Bindeligande für tumornekrosisfaktor
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
DE10399023I2 (de) * 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
GB2246569A (en) * 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
US20030064480A1 (en) * 1990-06-28 2003-04-03 Leander Lauffer Fusion proteins with immunoglobulin portions, the preparation and use thereof
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
ES2251009T3 (es) * 1990-06-28 2006-04-16 Sanofi-Aventis Deutschland Gmbh Proteinas de fusion con partes de inmunoglobulinas, su preparacion y uso.
ES2123515T3 (es) * 1991-03-29 1999-01-16 Immunex Corp Antagonistas de citoquinas a base de proteinas virales aisladas.
EP0537166B1 (de) * 1991-04-17 1999-07-07 Medisup International N.V. Neue wasserlösliche polypeptide mit hoher affinität für alpha- und beta- interferone
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
CA2121473C (en) * 1991-10-15 2001-05-01 Michael Mullarkey Methods and compositions for treating allergic reactions
DE69333027T2 (de) * 1992-03-30 2004-05-06 Immunex Corp., Seattle Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
JPH07509223A (ja) * 1992-04-30 1995-10-12 アムジェン インコーポレイテッド インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
IL101769A (en) * 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
US20050255104A1 (en) * 1993-01-29 2005-11-17 Centocor, Inc. Methods of treating psoriasis using anti-TNF receptor fusion proteins
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6579697B1 (en) * 1995-05-11 2003-06-17 Yeda Research And Development Co. Ltd. Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
IL111125A0 (en) * 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5741667A (en) * 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US7094564B1 (en) 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US7078493B1 (en) 1995-03-15 2006-07-18 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like genes
US8110659B1 (en) 1995-03-15 2012-02-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like genes
US7427492B1 (en) 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7070783B1 (en) 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
ZA966663B (en) 1995-08-17 1998-02-06 Genentech Inc Traf Inhibitors.
US6410252B1 (en) 1995-12-22 2002-06-25 Case Western Reserve University Methods for measuring T cell cytokines
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
WO1997033904A1 (en) * 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) * 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
WO1997034616A1 (en) * 1996-03-18 1997-09-25 Medical Science Systems, Inc. A method for periodontal disease treatment
US5912141A (en) * 1996-05-22 1999-06-15 President & Fellows Of Harvard College Nucleic acids encoding tumor virus susceptibility genes
ES2278390T3 (es) 1996-05-23 2007-08-01 The Scripps Research Institute Sistema de presentacion de antigenos de clase ii de cmh y procedimientos de activacion de linfocitos t cd4+.
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US5939281A (en) * 1996-09-16 1999-08-17 Case Western Reserve University Detecting alloreactivity
JP2001502912A (ja) * 1996-10-30 2001-03-06 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒト腫瘍壊死因子レセプター―ライク２
US6593456B1 (en) 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
EP0938548B1 (de) 1996-11-06 2008-08-06 The Regents of the University of California Tumor necrosis factor rezeptor abspaltendes enzym, dessen zubereitungen und verwendungen
US6930084B1 (en) 1996-11-06 2005-08-16 The Regents Of The University Of California Treating arthritis with TNF receptor releasing enzyme
US20050191661A1 (en) * 1996-11-06 2005-09-01 Tetsuya Gatanaga Treatment of inflammatory disease by cleaving TNF receptors
ATE429241T1 (de) 1996-11-27 2009-05-15 Immunex Corp Verfahren zur regulierung der stickstoffmonoxid- erzeugung
ES2207759T3 (es) 1996-12-06 2004-06-01 Amgen Inc. Terapia de combinacion que utiliza una proteina de union del factor de necrosis tumoral (tnf) en el tratamiento de enfermedades inducidas por el tnf.
EP2002846B1 (de) 1996-12-06 2017-01-25 Amgen Inc. Kombinationstherapie mit einem IL-1-Inhibitor zur Behandlung von IL-1-vermittelten Krankheiten
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU7705098A (en) * 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
AU2472899A (en) * 1998-01-27 1999-08-09 Millennium Pharmaceuticals, Inc. Novel molecules of the tnf receptor superfamily and uses therefor
US20030180310A1 (en) * 1998-04-29 2003-09-25 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US7115557B2 (en) * 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US7465785B2 (en) * 1999-03-08 2008-12-16 Genentech, Inc. Polypeptide encoded by a nucleic acid over-expressed in melanoma
PT1180159E (pt) 1999-05-28 2008-12-05 Targeted Genetics Corp Métodos e composições para abaixamento do nível de factor de necrose tumoral (tnf) nos distúrbios associados a tnf
EP1939300A1 (de) 1999-05-28 2008-07-02 Targeted Genetics Corporation Verfahren und Zusammensetzung zur Senkung des Spiegels des Tumornekrosefaktors (TNF) bei TNF-assoziierten Leiden
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
US7122631B2 (en) * 2000-02-22 2006-10-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2003525612A (ja) 2000-03-02 2003-09-02 ゼンコー ＴＮＦ−α関連障害の処置のための変種ＴＮＦ−αタンパク質の設計および発見
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
MXPA03002443A (es) 2000-09-22 2004-12-06 Immunex Corp Ensayos de clasificacion para agonistas o antagonistas del activador receptor de nf-kb.
HUP0303199A2 (hu) 2001-02-19 2003-12-29 Merck Patent Gmbh Eljárás T-sejt-epitópok azonosítására és csökkentett immunogenitású molekulák előállítására
US20030040119A1 (en) * 2001-04-11 2003-02-27 The Regents Of The University Of Michigan Separation devices and methods for separating particles
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl
WO2003026695A1 (en) * 2001-09-21 2003-04-03 Genset S.A. Agonists and antagonists of cylixin for the treatment of metabolic disorders
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
ES2322945T5 (es) * 2001-12-21 2012-10-17 Immunex Corporation Métodos para purficación de proteína
ES2311094T3 (es) 2002-02-27 2009-02-01 Immunex Corporation Composicion estabilizada de tnfr-fc que comprende arginina.
PL376821A1 (pl) 2002-03-27 2006-01-09 Immunex Corporation Sposoby zwiększania produkcji polipeptydów
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
EP1578799B8 (de) * 2002-12-02 2011-03-23 Amgen Fremont Inc. Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
CA2511823A1 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CN101039957A (zh) 2003-05-16 2007-09-19 因特缪恩公司 合成的趋化因子受体配体及其使用方法
US7892563B2 (en) * 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
EP2407470A3 (de) 2003-10-14 2015-06-10 F. Hoffmann-La Roche Ltd. Makrocyclische Carbonsäuren und Acylsulfonamide als Hemmer der HCV-Replikation
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
WO2005092927A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
AU2005240082B2 (en) * 2004-04-30 2009-07-23 Innatus Corporation Method and system to remove soluble TNFR1,TNFR2, and IL2 in patients
AU2005273968A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
CA2629323A1 (en) * 2005-11-10 2007-05-24 The University Of North Carolina At Chapel Hill Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
US7785834B2 (en) * 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
US7504106B2 (en) * 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
AU2006344750A1 (en) * 2006-06-15 2007-12-27 Targeted Genetics Corporation Methods for treating target joints in inflammatory arthritis using AAV vectors encoding a TNF antagonist
US20100093829A1 (en) * 2006-07-07 2010-04-15 Gorman James R Methods for preventing, postponing or improving the outcome of spinal device and fusion procedures
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US20090264353A1 (en) * 2007-10-19 2009-10-22 Santaris Pharma A/S Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
WO2008097525A2 (en) 2007-02-05 2008-08-14 Potentia Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
CA2679941C (en) 2007-03-02 2016-09-20 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
ES2517603T3 (es) 2008-04-07 2014-11-03 Bayer Healthcare, Llc Procedimientos de producción recombinante de glucoproteínas
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
BR112012013330A2 (pt) * 2009-12-02 2017-03-28 Acceleron Pharma Inc composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
RS59743B1 (sr) 2010-01-15 2020-02-28 Kirin Amgen Inc Formulacija antitela protiv il-17ra i terapeutski režimi za lečenje psorijaze
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
US9012178B2 (en) 2010-08-05 2015-04-21 Amgen Inc. Dipeptides to enhance yield and viability from cell cultures
CN102382850A (zh) * 2010-09-01 2012-03-21 山东新时代药业有限公司 新型人肿瘤坏死因子受体-Fc融合基因及其产物蛋白
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
EP2718328A4 (de) 2011-06-08 2014-12-24 Acceleron Pharma Inc Zusammensetzungen und verfahren zur erhöhung der halbwertszeit von serum
ES2625045T3 (es) 2011-07-01 2017-07-18 Amgen Inc. Cultivo de células de mamífero
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
US20140315187A1 (en) 2011-09-02 2014-10-23 Amgen Inc. Pharmaceutical Product and Method of Analysing Light Exposure of a Pharmaceutical Product
EP2771294B1 (de) 2011-10-25 2017-12-13 Corning Incorporated Pharmazeutische delaminationsresistente glasbehälter mit pharmazeutischen wirkstoffen
US10350139B2 (en) 2011-10-25 2019-07-16 Corning Incorporated Pharmaceutical glass packaging assuring pharmaceutical sterility
AR089231A1 (es) 2011-12-15 2014-08-06 Amgen Inc Metodo de floculacion
LT2895188T (lt) 2012-09-11 2018-04-10 Coherus Biosciences, Inc. Aukšto grynumo ir geros išeigos teisingos struktūros etanerceptas
WO2014109858A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
TWI720289B (zh) 2013-03-14 2021-03-01 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
EP3395423B1 (de) 2013-03-14 2023-09-20 Amgen Inc. Entfernung von ausgelaufenen affinitätsreinigungsliganden
TWI683666B (zh) 2013-03-15 2020-02-01 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
US9707155B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9713572B2 (en) 2013-04-24 2017-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707153B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717648B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717649B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
MX382786B (es) 2013-10-31 2025-03-13 Amgen Inc Uso de monensina para regular la glicosilacion de proteinas recombinantes.
WO2015105609A1 (en) 2014-01-13 2015-07-16 Amgen Inc. Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
CN113774084B (zh) 2014-01-29 2024-04-16 美国安进公司 过表达n-糖基化途径调节基因以调节重组蛋白的糖基化
US10106829B2 (en) 2014-01-29 2018-10-23 Amgen Inc. Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
CN106456751B (zh) 2014-03-31 2021-02-02 安姆根K-A有限公司 治疗指甲和头皮银屑病的方法
PT3926051T (pt) 2014-06-04 2024-06-20 Amgen Inc Métodos de colheita de culturas de células de mamíferos
ES2727380T3 (es) 2014-11-19 2019-10-15 Amgen Inc Cuantificación de resto glucano en glucoproteínas recombinantes
EP3227454B1 (de) 2014-12-01 2020-01-29 Amgen Inc. Verfahren zur manipulation des glycangehalts eines glycoproteins
EP3268042B1 (de) 2015-03-13 2024-11-27 Samsung Bioepis Co., Ltd. Anti-tnf-alpha-polypeptid-zusammensetzung und verwendung davon
KR102446838B1 (ko) 2016-10-21 2022-09-26 암젠 인크 약학적 제형 및 그의 제조 방법
KR20210005689A (ko) 2018-05-01 2021-01-14 암젠 인크 조절된 글리칸 프로파일을 갖는 항체
US11952399B2 (en) 2018-12-18 2024-04-09 Amgen Inc. Methods for purifying proteins
CA3241882A1 (en) 2021-12-29 2023-07-06 Bristol-Myers Squibb Company Generation of landing pad cell lines

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675285A (en) * 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
JPS61293924A (ja) * 1985-06-23 1986-12-24 Asahi Chem Ind Co Ltd 生理活性物質の受容タンパク
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
PT88641B (pt) * 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
DE721983T1 (de) * 1988-01-22 2002-07-04 Zymogenetics, Inc. Verfahren zur herstellung von biologisch-aktive Dimerpeptiden
GB8806339D0 (en) * 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB8807803D0 (en) * 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0394827A1 (de) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimärische CD4-Immunoglobulin-Polypeptide
DE3922089A1 (de) * 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
CA2017025C (en) * 1989-05-18 2008-07-22 David Wallach Tumor necrosis factor binding protein ii, its purification and antibodies thereto
IL95031A (en) * 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (de) * 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
ES2251009T3 (es) * 1990-06-28 2006-04-16 Sanofi-Aventis Deutschland Gmbh Proteinas de fusion con partes de inmunoglobulinas, su preparacion y uso.
GB9022648D0 (en) * 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells

Also Published As

Publication number Publication date
ES2080809T4 (es) 2012-12-20
EP0418014A1 (de) 1991-03-20
USRE36755E (en) 2000-06-27
NL300008I1 (nl) 2000-08-01
LU90591I2 (fr) 2000-07-31
DK0418014T3 (da) 1996-01-22
EP0418014B1 (de) 1995-12-20
US5395760A (en) 1995-03-07
GR3019333T3 (en) 1996-06-30
NL300008I2 (nl) 2000-12-01
DE10075011I1 (de) 2003-06-12
DE69024291T2 (de) 1996-10-31
ATE131871T1 (de) 1996-01-15
ES2080809T3 (es) 1996-02-16
DE69024291D1 (de) 1996-02-01

Similar Documents

Publication Publication Date Title
ATE131871T1 (de) Rezeptoren für tumornekrosisfaktor-alpha und - beta
CA2065346A1 (en) Tumor necrosis factor-.alpha. and-.beta. receptors
ES2103706T3 (es) Receptores de interleuquina-4.
ATE169956T1 (de) Dna, die für proteine kodiert, die menschliches il-1 binden
ES2172502T3 (es) Receptores tipo ii de interleucina 1.
DE69016508D1 (de) Interleukin-7-Rezeptoren.
HU901326D0 (en) Recombinant protein receptor and process for production thereof
DE3851035D1 (de) Interleukin-7.
DK0494260T3 (da) Receptorer for granulocytkolonistimulerende faktor